Capsid Protein

Updated: 2026-07-15

Overview

Capsid proteins are the primary structural components of viral capsids, the protein shells that enclose viral genomes. These proteins self-assemble into highly organized structures (icosahedral, helical, or complex) to protect nucleic acids and facilitate host cell entry. Their sequences and folding patterns are virus-specific, making them key targets for antiviral therapies and diagnostic tools. In biotech and pharmaceutical industries, recombinant capsid proteins are produced for vaccine development (e.g., HPV vaccines) and viral vector systems (e.g., AAV gene therapy). Their ability to self-assemble into nanoparticles also enables applications in drug delivery and nanomaterials.

Physical and Chemical Properties

Capsid proteins exhibit virus-dependent molecular weights (commonly 20-50 kDa) and isoelectric points. They typically form oligomers via non-covalent interactions (hydrogen bonds, hydrophobic effects). Stability varies: some resist extreme pH/temperature (e.g., hepatitis B core protein), while others disassemble readily (e.g., rhinovirus capsids). Purified capsid proteins are usually lyophilized powders soluble in PBS or Tris buffers. Analytical methods include SDS-PAGE (purity verification), dynamic light scattering (assembly state), and electron microscopy (morphology). Critical quality attributes for industrial use include endotoxin levels (<1 EU/μg) and aggregation status.

Main Applications

1. Vaccine Development: Capsid proteins serve as antigens in subunit vaccines (e.g., Gardasil targets HPV L1 protein). Virus-like particles (VLPs) mimic native virions without genetic material. 2. Gene Therapy: Adeno-associated virus (AAV) capsids are engineered for tissue-specific gene delivery. Capsid modifications alter tropism and immune evasion. 3. Nanotechnology: Engineered capsids package drugs or imaging agents. Their uniform size (20-400 nm) and modifiable surfaces make them ideal nanocarriers.

Safety and Storage

Non-infectious recombinant capsid proteins generally require BSL-1 handling, but pathogen-derived variants may need BSL-2 precautions. Always verify inactivation status (e.g., by SDS treatment or heat). Use PPE when handling lyophilized powders to prevent inhalation. Store at -20°C or -80°C with desiccants. Avoid repeated freeze-thaw cycles by aliquoting. For working solutions, add stabilizers (e.g., 5-10% glycerol) and protease inhibitors if needed. Monitor aggregation via dynamic light scattering over time.

B2B Procurement Guide

For research: Specify virus species (e.g., AAV2 capsid), purity (>90% by SDS-PAGE), and endotoxin levels (<1 EU/μg). Request analytical certificates (mass spec, DLS). Vendors include Thermo Fisher, Sino Biological, and specialized VLP producers. For industrial scale: Partner with GMP manufacturers for clinical-grade material. Key considerations: scalability of expression systems (E. coli, insect cells), batch consistency, and regulatory documentation. Lead times for custom capsids can exceed 6 months. Budget $5,000-$50,000 per gram for GMP-grade proteins.